GT Biopharma (GTBP) & The Race To Commercialize Breakthrough Immunotherapies

The recent events surrounding natural killer (NK) cell therapy have begun to…

Marijuana Stocks: Humble Beginnings Could Lead To Big Opportunity

Marijuana Stocks Update To GT Biopharma (GTBP). CLICK HERE To Read Full…

$CARA Begins Phase 3 Program

Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative…

$XXII Appoints Gregg M. Gellman As Director of Business Development & Regulatory Affairs

22nd Century Announces Strategic Hire to Facilitate FDA Applications for Modified Risk…

$OXIS Executes Exclusive Worldwide Cancer Therapy Licensing Agreement

Oxis Biotech Licenses Exclusive Worldwide Rights To Novel Cancer Therapy TAMPA, Fla.,…

$OXIS Biotech, Inc. Licenses Worldwide Rights to Cancer Therapy with Positive FDA Phase I Study Results

Oxis Biotech, a wholly-owned subsidiary of Oxis International, Inc. (OTCQB: OXIS) is…